Vial Announces the Addition of Dr. Christopher Sweeney of SAiGENCI and the University of Adelaide to their Oncology CRO Scientific Advisory Board

San Francisco, CA. December 19, 2022 — Vial, a global tech-enabled CRO providing next-generation clinical trial management services, announced the addition of Christopher Sweeney, MBBS, to Vial’s scientific advisory board (SAB). Dr. Sweeney will work closely with the company’s leadership team to shape the scientific strategy of Vial’s Oncology CRO products and services.

“We are beyond thrilled that an eminent scientist such as Dr. Sweeney has decided to join our CRO’s Oncology SAB. He has had a long and successful career in oncology clinical research, and we are excited he is willing to share that wisdom with us,” said Richard McCormick Jr., VP of Oncology at Vial.

“I am happy to share my knowledge of oncology science, novel strategies for efficient clinical trial conduct, and technological trends that can help bring inspiration and efficiency to the clinical research landscape,” said Dr. Sweeney.

Dr. Sweeney is the inaugural Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI), and a professor of medicine at the University of Adelaide. Dr. Sweeney completed his medical education at the University of Adelaide before accomplishing his internship at Royal Adelaide Hospital in Australia. He completed his residency training in internal medicine at Gundersen Lutheran Medical Center in Wisconsin, and his fellowship in hematology and oncology at Indiana University School of Medicine. He then spent 7 years on faculty at Indiana and was appointed Associate Director for Clinical Research for the Simon Cancer Center. Dr. Sweeney joined the Lank Center for Genitourinary Oncology at Dana-Farber Cancer and Harvard Medical School in 2009 and was promoted to full Professor of Medicine at Harvard Medical School in 2018.

Dr. Sweeney has over 25 years of experience in hematology and oncology and leading clinical trials as well preclinical drug discovery and translational research. He has either lead or contributed to over 200 peer-reviewed original research publications as well as more than 50 peer-reviewed teaching papers and more than 25 review articles and book chapters. He has been a first or senior author of papers published in high-ranking journals such as the New England Journal of Medicine, Lancet, Nature and Nature Medicine, Journal of Clinical Oncology and Annals of Oncology. He has led several clinical trials that have changed and/or informed the care of men with prostate and bladder cancer and germ cell tumors.

Dr. Sweeney’s research focuses on drug development for all cancers but has a special emphasis on prostate and testicular cancer, and his work has received funding from the National Institutes of Health and the Department of Defense. He has received several awards from the Prostate Cancer Foundation, including the Special Challenge Award and the ICECaP Award in 2012 and 2018 which was also awarded the Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award (joint awardee with ICECaP biostatisticians by the American Statistical Association in 2021). Moreover, he was study co-chair of a global investigator-sponsored phase 3 trial ENZAMET which was awarded Clinical Trial of the Year Award by the Australian Clinical Trials Alliance Research in 2020.

About Vial: Vial is a tech-enabled, next-generation CRO that promises faster and higher-quality execution of trials for less cost. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. Vial’s technology platform combines modern, intuitive eSourceEDC, and ePRO into one connected system, streamlining site processes and enabling considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CROOphthalmology CROOncology CROGastroenterology CRONeurology CRO, and Cardiology CRO). Vial is a San Francisco, California-based company with over 125 employees.

Contact Us

By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.